Biotron Limited (AU:BIT) has released an update.
Biotron Limited has announced encouraging results from their Phase 2 HIV-1 trials for the antiviral drug BIT225, revealing a significant impact on immune and inflammation biomarkers. Unlike current antiretroviral treatments, BIT225 shows promise in targeting persistent HIV reservoirs that lead to lifelong treatment. The Sydney trial, specifically focusing on immune non-responders, demonstrated that BIT225 may help uncover and eliminate hidden virus cells, a breakthrough that could revolutionize HIV treatment.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.
